Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.

VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.

Share this video  

Sleep Europe 2026 | Distinguishing augmentation from disease progression and treatment intolerance in RLS

Diego Garcia-Borreguero, MD, PhD, Sleep Research Institute, Madrid, Spain, discusses how to distinguish augmentation, an iatrogenic worsening of symptoms caused by dopaminergic drugs, from treatment intolerance and disease progression in restless legs syndrome (RLS). Dr Garcia-Borreguero highlights that, unlike intolerance or disease progression, augmentation leaves patients worse than before treatment, develops over weeks to months rather than years, and improves when the dose is reduced or treatment is discontinued. This interview took place at Sleep Europe 2026, which was held in Maastricht, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

The differentiation is not easy. Augmentation is an increase in symptom severity as a result of treatment. So by essence, it’s iatrogenic. Iatrogenic to one type of drugs, namely to the dopamine agonist. Well, let’s say to dopaminergic drugs in general, but the most used ones are the dopamine agonists. Usually the main differentiation between augmentation and intolerance is that while intolerance, there’s still some effect of the medication, the patient is still doing better than when treatment is interrupted...

The differentiation is not easy. Augmentation is an increase in symptom severity as a result of treatment. So by essence, it’s iatrogenic. Iatrogenic to one type of drugs, namely to the dopamine agonist. Well, let’s say to dopaminergic drugs in general, but the most used ones are the dopamine agonists. Usually the main differentiation between augmentation and intolerance is that while intolerance, there’s still some effect of the medication, the patient is still doing better than when treatment is interrupted. During augmentation, the patient is far worse than before the treatment was started, was initiated. So it’s really making the patient worse. It’s something quite similar to what what we see in the iatrogenic cause in the hyperalgesia produced by analgesics. Quite, I mean, it is making the disease worse. The differentiation between augmentation and the progression of disease is more difficult. The main difference will be that the development of augmentation is relatively quick. It’s going to be a question of weeks or months at most, while the progression in progression of the disease is something that happens over years or decades. Very, very, very slowly. There is one additional thing that could be used in clinical practice, although it’s difficult to implement. And it’s related. I mean, when the disease is progressing, if you interrupt treatment, if you discontinue treatment, the patient, the RLS symptoms will not improve. In augmentation, if you discontinued or reduced the dose, because it is iatrogenic, it will improve over several weeks. That can also be used as a marker.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.